| Not Yet Recruiting | Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy NCT07535138 | Air Force Military Medical University, China | EARLY_Phase 1 |
| Recruiting | Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease NCT07507201 | The Children's Hospital of Zhejiang University School of Medicine | EARLY_Phase 1 |
| Not Yet Recruiting | A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Im NCT07445906 | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients NCT07022574 | University of California, Los Angeles | N/A |
| Recruiting | Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN NCT07390123 | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 |
| Recruiting | A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immu NCT07389499 | Grit Biotechnology | EARLY_Phase 1 |
| Not Yet Recruiting | The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy NCT07360002 | Keda Lu | N/A |
| Recruiting | CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease NCT07305116 | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 |
| Recruiting | A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy NCT07305974 | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | Phase 2 |
| Recruiting | Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease NCT06989359 | ADARx Pharmaceuticals, Inc. | Phase 2 |
| Not Yet Recruiting | Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA NCT07052981 | Guixia Ding | Phase 3 |
| Withdrawn | An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment o NCT06926985 | Jieyang People's Hospital | EARLY_Phase 1 |
| Recruiting | RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study NCT06926244 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) NCT06676579 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Monthly Dosing of Atacicept in IgAN NCT07020923 | Vera Therapeutics, Inc. | Phase 2 |
| Recruiting | Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial NCT07056595 | Botkin Hospital | N/A |
| Not Yet Recruiting | A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases NCT06786338 | Suzhou Sanegene Bio Inc. | Phase 2 |
| Recruiting | A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria NCT06819826 | Biocity Biopharmaceutics Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy ( NCT06687174 | Wuhan Createrna Science and Technology Co., Ltd | Phase 2 |
| Recruiting | Efficacy and Safety of Telitacicept in IgAN NCT06654596 | Ruijin Hospital | N/A |
| Enrolling By Invitation | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept NCT06674577 | Vera Therapeutics, Inc. | Phase 2 |
| Recruiting | A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide NCT06676007 | Sichuan Provincial People's Hospital | — |
| Recruiting | Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN NCT06670352 | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 |
| Active Not Recruiting | To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy NCT07098897 | The Affiliated Hospital of Xuzhou Medical University | Phase 3 |
| Completed | Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases NCT04689074 | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | — |
| Recruiting | Raman Spectroscopy Diagnosis of Kidney Diseases NCT06760845 | Zunsong Wang | — |
| Terminated | A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) NCT03841448 | Alnylam Pharmaceuticals | Phase 2 |
| Completed | An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA NCT01269021 | Zhi-Hong Liu, M.D. | N/A |